Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer."

被引：0
|
作者：
Apsey, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Roy, V. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Pockaj, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Northfelt, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sticca, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Nikcevich, D. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Mattar, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Fitch, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Perez, E. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Mayo Clin Arizona, Phoenix, AZ USA
[2] Mayo Clin Minnesota, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Univ N Dakota, Grand Forks, ND 58201 USA
[5] Duluth Clin, Duluth, MN USA
[6] Wichita Community Clin Oncol Program, Wichita, KS USA
[7] Mayo Clin Florida, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
623
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial
    André, T
    Colin, P
    Louvet, C
    Gamelin, E
    Bouche, O
    Achille, E
    Colbert, N
    Boaziz, C
    Piedbois, P
    Tubiana-Mathieu, N
    Boutan-Laroze, A
    Flesch, M
    Buyse, M
    de Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2896 - 2903
  • [32] Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial
    Di Cosimo, S.
    Laverde, N.
    Cazzaniga, M. E.
    Generali, D.
    Bianchi, G. V.
    Tagliabue, E.
    Torri, V.
    Crippa, F.
    Paolini, B.
    Scaperrotta, G.
    Gulino, A.
    Tripodo, C.
    Colombo, M. P.
    Folli, S.
    de Braud, F. G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment
    Barakat, RR
    Almadrones, L
    Venkatraman, ES
    Aghajanian, C
    Brown, C
    Shapiro, F
    Curtin, JP
    Spriggs, D
    GYNECOLOGIC ONCOLOGY, 1998, 69 (01) : 17 - 22
  • [34] A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy.
    Minton, SE
    Garcia, R
    Bowman, T
    Dalton, W
    Muro-Cacho, C
    Diaz, N
    Cox, C
    Dupont, E
    Reintgen, D
    Shons, A
    Fields, K
    Sullivan, D
    Jove, R
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 300 - 300
  • [35] Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis.
    Lee, HG
    Lee, JJ
    Jung, KH
    Kwon, Y
    Shin, EH
    Chung, KW
    Shin, KH
    Kim, EA
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 29S - 29S
  • [36] Assessment of Practice Patterns Following Publication of the SSO–ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer
    Sarah M. DeSnyder
    Kelly K. Hunt
    Benjamin D. Smith
    Meena S. Moran
    Suzanne Klimberg
    Anthony Lucci
    Annals of Surgical Oncology, 2015, 22 : 3250 - 3256
  • [37] A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer
    Bellon, Jennifer R.
    Chen, Yu-Hui
    Rees, Rebecca
    Taghian, Alphonse G.
    Wong, Julia S.
    Punglia, Rinaa S.
    Shiloh, Ron Y.
    Warren, Laura E. G.
    Krishnan, Monica S.
    Phillips, John
    Pretz, Jennifer
    Jimenez, Rachel
    Macausland, Stephanie
    Pashtan, Itai
    Andrews, Chelsea
    Isakoff, Steven J.
    Winer, Eric P.
    Tolaney, Sara M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (01): : 45 - 52
  • [38] A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer
    Hurvitz, S. A.
    Bosserman, L. D.
    Leland-Jones, B.
    Thirwell, M.
    Allison, M. K.
    Barstis, J.
    Molthrop, D.
    Quan, E.
    Upadhyaya, G.
    Slamon, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer
    DeSnyder, Sarah M.
    Hunt, Kelly K.
    Smith, Benjamin D.
    Moran, Meena S.
    Klimberg, Suzanne
    Lucci, Anthony
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (10) : 3250 - 3256
  • [40] Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer
    Dunderdale, J.
    Kulkarni, S.
    BREAST DISEASES, 2016, 27 (02): : 149 - 150
12345